v3.26.1
Revenue
 6 Months Ended
Jun. 30, 2026
Revenue from Contract with Customer [Abstract]  
Revenue Revenue
The Company recorded the following revenues for the three and six months ended June 30, 2026 and 2025:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
ORLADEYO$158,202 $156,837 $306,549 $291,080 
License and other revenues60,048 6,516 68,114 17,807 
Total revenues$218,250 $163,353 $374,663 $308,887 

ORLADEYO revenue includes product sales and royalties. License and other revenues includes revenue recognized related to the Kaken License Agreement and Neopharmed License Agreement (see “Note 12—Collaborative and Other Relationships”), quarterly royalty payments from BioCryst Ireland Limited (see “Note 1—Significant Accounting Policies and Concentrations of Risk”), and product sales and royalty revenue related to peramivir.
Revenues from customers in the U.S. represented approximately 97% and 96% of ORLADEYO revenues for the three and six months ended June 30, 2026, respectively. Revenues from customers in the U.S. represented approximately 89% of ORLADEYO revenues for the three and six months ended June 30, 2025.